N-acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in serbs: Unprecedented high prevalence of rapid acetylators in a white population

Journal of Clinical Pharmacology

Volumn 51, Issue 7, 2011, Pages 994-1003

  Djordjevic, Natasa ^a,b   Carrillo, Juan Antonio ^c   Ueda, Nobuhisa ^a   Gervasini, Guillermo ^c   Fukasawa, Takashi ^a   Suda, Akira ^a   Jankovic, Slobodan ^b   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

^c UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

caffeine; genotype; NAT2; phenotype; Serbs

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; N ACYLTRANSFERASE 1; UNCLASSIFIED DRUG;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; CIGARETTE SMOKING; ENZYME ACTIVITY; FEMALE; GENDER; GENE FREQUENCY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; MALE; MOLECULAR PROBE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; SERBIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ACETYLATION; ADOLESCENT; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SERBIA; URACIL; URIC ACID; XANTHINES; YOUNG ADULT;

EID: 79958796617     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010377630     Document Type: Article

References (47)

1. Meisel P. Arylamine N-acetyltransferases and drug response. Pharmacogenomics. 2002 ; 3: 349-366 (Pubitemid 34567572)
2. Westwood IM, Kawamura A, Fullam E, et al. Structure and mechanism of arylamine N-acetyltransferases. Curr Top Med Chem. 2006 ; 6: 1641-1654 (Pubitemid 44304619)
3. Boukouvala S, Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev. 2005 ; 37: 511-564 (Pubitemid 41434161)
4. Krul C, Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998 ; 709: 27-34 (Pubitemid 28238415)
5. Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev. 1999 ; 8: 683-692 (Pubitemid 30064536)
6. Bakayev VV, Mohammadi F, Bahadori M, et al. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol. 2004 ; 60: 467-471 (Pubitemid 39350159)
7. Pompeo F, Brooke E, Kawamura A, Mushtaq A, Sim E. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics. 2002 ; 3: 19-30 (Pubitemid 34285236)
8. Rihs HP, John A, Scherenberg M, Seidel A, Bruning T. Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. Clin Chim Acta. 2007 ; 376: 240-243 (Pubitemid 44880995)
9. Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev. 1997 ; 6: 225-231 (Pubitemid 27172886)
10. Kang TS, Jin SK, Lee JE, Woo SW, Roh J. Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups. J Clin Pharm Ther. 2009 ; 34: 709-718
11. Hein DW. N-acetyltransferase single nucleotide polymorphisms: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol. 2009 ; 5: 353-366
12. Muscat JE, Pittman B, Kleinman W, et al. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers. Biochem Pharmacol. 2008 ; 76: 929-937
13. Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab. 2008 ; 9: 487-497 (Pubitemid 352034203)
14. Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol. 2008 ; 64: 381-385 (Pubitemid 351322359)
15. Lindroos K, Liljedahl U, Raitio M, Syvanen AC. Minisequencing on oligonucleotide microarrays: comparison of immobilisation chemistries. Nucleic Acids Res. 2001 ; 29: E69
16. Lindroos K, Sigurdsson S, Johansson K, Ronnblom L, Syvanen AC. Multiplex SNP genotyping in pooled DNA samples by a 4-color microarray system. Nucleic Acids Res. 2002 ; 30: e70
17. Lovmar L, Fredriksson M, Liljedahl U, Sigurdsson S, Syvanen AC. Quantitative evaluation by minisequencing and microarrays reveals accurate multiplexed SNP genotyping of whole genome amplified DNA. Nucleic Acids Res. 2003 ; 31: e129
18. Anitha A, Banerjee M. Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. Int J Mol Med. 2003 ; 11: 125-131
19. Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics. 1999 ; 9: 103-111 (Pubitemid 29176729)
20. Carrillo JA, Christensen M, Ramos SI, et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit. 2000 ; 22: 409-417 (Pubitemid 30622112)
21. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics. 1996 ; 6: 121-149 (Pubitemid 26153358)
22. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2, and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr. 2007 ; 21: 190-200
23. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat. 1998 ; 52: 119-126
24. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther. 2007 ; 81: 270-283 (Pubitemid 46174825)
25. Le Marchand L, Sivaraman L, Franke AA, et al. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies?. Cancer Epidemiol Biomarkers Prev. 1996 ; 5: 449-455 (Pubitemid 26182659)
26. Rasmussen BB, Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit. 1996 ; 18: 254-262 (Pubitemid 26159576)
27. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992 ; 52: 643-658 (Pubitemid 23001871)
28. Miners JO, Birkett DJ. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol. 1996 ; 27: 245-249 (Pubitemid 26129183)
29. Saruwatari J, Nakagawa K, Shindo J, et al. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther. 2002 ; 72: 200-208 (Pubitemid 35034498)
30. Cascorbi I, Drakoulis N, Brockmoller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995 ; 57: 581-592
31. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther. 1994 ; 55: 293-304 (Pubitemid 24183729)
32. Zhu Y, Doll MA, Hein DW. Functional genomics of C190T single nucleotide polymorphism in human N-acetyltransferase 2. Biol Chem. 2002 ; 383: 983-987 (Pubitemid 34874102)
33. Leff MA, Fretland AJ, Doll MA, Hein DW. Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J Biol Chem. 1999 ; 274: 34519-34522 (Pubitemid 129509483)
34. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002 ; 506-507: 65-77 (Pubitemid 35286541)
35. Teixeira RL, Silva FP, Silveira AR, et al. Sequence analysis of NAT2 gene in Brazilians: identification of undescribed single nucleotide polymorphisms and molecular modeling of the N-acetyltransferase 2 protein structure. Mutat Res. 2010 ; 683: 43-49
36. Teixeira RL, Miranda AB, Pacheco AG, et al. Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil. Mutat Res. 2007 ; 624: 31-40 (Pubitemid 47595332)
37. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A. 1991 ; 88: 5237-5241 (Pubitemid 21914719)
38. Zang Y, Zhao S, Doll MA, Christopher States J, Hein DW. Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2. Pharmacogenet Genomics. 2007 ; 17: 37-45 (Pubitemid 46183790)
39. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2, and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003 ; 59: 303-312 (Pubitemid 37100349)
40. Walraven JM, Trent JO, Hein DW. Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1. Drug Metab Rev. 2008 ; 40: 169-184 (Pubitemid 351220644)
41. Zhu Y, Hein DW. Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenomics J. 2008 ; 8: 339-348
42. Jiao L, Doll MA, Hein DW, et al. Haplotype of N-Acetyltransferase 1 and 2 and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007 ; 16: 2379-2386 (Pubitemid 351196371)
43. Soucek P, Skjelbred CF, Svendsen M, et al. Single-track sequencing for genotyping of multiple SNPs in the N-acetyltransferase 1 (NAT1) gene. BMC Biotechnology. 2004 ; 4: 28
44. Doll MA, Hein DW. Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1. Anal Biochem. 2002 ; 301: 328-332 (Pubitemid 34158198)
45. Ghotbi R, Gomez A, Milani L, et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J. 2009 ; 9: 208-217
46. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics. 2002 ; 12: 375-383 (Pubitemid 34816417)
47. Straka RJ, Burkhardt T, Lang NP, Hadsall KZ, Tsai MY. Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects. J Clin Pharmacol. 2006 ; 46: 802-811 (Pubitemid 43882804)